Solazyme CTO Unloads $28,969 in Stock (SZYM)
Solazyme (NASDAQ:SZYM) CTO Peter Licari unloaded 3,125 shares of the company’s stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $9.27, for a total value of $28,968.75. Following the sale, the chief technology officer now directly owns 258,966 shares in the company, valued at approximately $2,400,615. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Solazyme (NASDAQ:SZYM) traded down 2.98% on Thursday, hitting $8.78. 1,427,321 shares of the company’s stock traded hands. Solazyme has a one year low of $8.00 and a one year high of $15.00. The stock has a 50-day moving average of $9.49 and a 200-day moving average of $10.83. The company’s market cap is $691.0 million. Solazyme also was the target of a significant growth in short interest in August. As of August 15th, there was short interest totalling 19,140,646 shares, a growth of 7.7% from the July 31st total of 17,778,221 shares. Based on an average daily volume of 822,393 shares, the days-to-cover ratio is currently 23.3 days. Approximately 33.5% of the company’s stock are short sold.
Solazyme (NASDAQ:SZYM) last issued its quarterly earnings data on Wednesday, July 30th. The company reported ($0.43) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.36) by $0.07. The company had revenue of $15.94 million for the quarter, compared to the consensus estimate of $17.13 million. During the same quarter in the prior year, the company posted ($0.28) earnings per share. The company’s quarterly revenue was up 42.6% on a year-over-year basis. Analysts expect that Solazyme will post $-1.71 EPS for the current fiscal year.
Solazyme, Inc operates as a renewable oil production company. The Company fuels include microbial-derived jet fuels, bio-diesels, and renewable diesels.
Receive News & Ratings for Solazyme Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solazyme Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.